Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib combinations in quadruple wild-type mCRC
NCT03457896Phase 2Unknown
- Sponsor
- NSABP Foundation
- Start
- May 2018
- Primary completion
- Sep 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of neratinib in metastatic colorectal cancer (mCRC) (2 arms), sponsored by NSABP Foundation. Primary endpoints: Progression-Free Survival at 6 months and Progression-Free Survival with Neratinib + Cetuximab at 6 months. Status: unknown.
02
Drugs
neratinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03457896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03457896.